Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials

Get ActivE Study for At-risk Youth

NCT06829953
Recruiting
Conditions Anhedonia, Depression and Suicide Ideati...
Phase NA
Enrollment 75
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The study will adapt and deploy a digital Behavioral Activation app with mobile sensing, supported by health coaches, that encourages youth to engage in positive activities. The study has the potential to offer a low-cost and scalable behavioral intervention that may decrease risk of suicide among at-risk youth. This research will examine specifically whether an intervention involving an app called Vira, combined with health coaching (GET ActivE) can improve enjoyment for teens coping with depression. Research participants will be randomly assigned to one of two study intervention. One study intervention involves a) downloading an app called Vira and engaging by responding to a daily question, and b) participating in a conversation via text, phone, or messages through an appt with a health coach. The health coach will use the Vira app and principles from evidence-based therapy and behavior change to provide users with insights to sustain well-being and better manage risk factors for suicidal thoughts and behaviors such as depressed mood and behavioral withdrawal. The second study intervention involves downloading an app called EARS and responding to a daily question.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: GET ActivE — The GET ActivE health coach will review data from the Vira app and send nudges to the participant with insights encouraging them to engage in activities that bring enjoyment or pleasure.
  • Behavioral: Treatment As Usual — Participants randomized to Treatment As Usual may have access to activity data from an app and receive summary information about activity patterns at the end of their participation.

Primary Outcomes

  • GET ActivE Feasibility (3 months)
  • Response to Health coach contacts (3 months)
  • GET ActivE Acceptability (Post intervention follow up; up to 3 months)
  • GET ActivE Appropriateness (Post intervention follow up; up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-27
Completion: 2026-12-31
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Pittsburgh
Collaborators: Children's Hospital of Philadelphia, University of Oregon, National Institute of Mental Health (NIMH), Columbia University
Principal Investigators:
  • Jamie Zelazny, PhD, MPH, RN (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Brandie George-Milford, MA
412-246-5629
georgeba2@upmc.edu
Morgan Rose, BS
978-799-9419
rosem5@upmc.edu
Jami Young, PhD
267-425-1328
youngjf@chop.edu
Children's Hospital of Philadelphia
Interventions
  • Behavioral: GET ActivE — The GET ActivE health coach will review data from the Vira app and send nudges to the participant with insights encouraging them to engage in activities that bring enjoyment or pleasure.
  • Behavioral: Treatment As Usual — Participants randomized to Treatment As Usual may have access to activity data from an app and receive summary information about activity patterns at the end of their participation.
Study Locations (2 sites)
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania 15213 United States
Eligibility Criteria
Inclusion Criteria: * Adolescents age 12-18 * Current moderate to severe depression (PHQ-9-M \> 11) * Current clinically significant anhedonia, operationalized as PHQ-9-M anhedonia item score \> 1 * English language fluency and literacy level sufficient to engage in study protocol * Willing to download the app on their smart phones Exclusion Criteria: * Evidence of mania, psychosis, or developmental disability precluding comprehension of study procedures per electronic health record review and phone screen.
Conditions Breast Cancer Early Stage Breast Cancer ...
Phase Not Applicable
Enrollment 1001
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to ascertain the outcomes following partial breast reconstruction using chest wall perforator flaps after breast conservation surgery.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Surgical Complications (Within 30 days of surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-06-01
Completion: 2026-05-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1001 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust
Collaborators: Oxford University Hospitals NHS Trust
Principal Investigators:
  • Amit Agrawal (PRINCIPAL_INVESTIGATOR) - Cambridge University Hospitals NHS Foundation Trust
Contact Information
Study Contact:
Amit Agrawal, DM, FRCS
+44 1223 216315
amit.agrawal2@nhs.net
Amit Agrawal, DM, FRCSsurg
+44 1223 216 315
amit.agrawal2@nhs.net
Cambridge University Hospitals NHS Trust
Amit Agrawal
Cambridge University Hospitals NHS Trust
Interventions
N/A
Study Locations (1 sites)
Cambridge University Hospitals NHS Trust, Cambridge, Cambridgeshire CB2 0QQ United Kingdom
Eligibility Criteria
Inclusion Criteria: * Patients undergoing partial breast reconstruction using CWPF for primary breast cancer * Delayed correction of breast deformity following previous BCS * Each surgeon is to have performed a minimum of 10 CWPFs * Each centre anticipates completing a minimum of 10/year Exclusion Criteria: * Patients undergoing volume displacement BCS * Patients undergoing mastectomy +/- immediate breast reconstruction
Conditions Type 2 Diabetes Mellitus (T2DM)
Phase PHASE3
Enrollment 207
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of BGM0504 in patients with type 2 diabetes (T2D) with poor glycemic control only through diet and exercise. The main purpose is to evaluate the clinical efficacy of BGM0504 injection monotherapy for 32 weeks compared with placebo in Chinese patients with type 2 diabetes with poor glycemic control only through diet and exercise, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Drug: 5 mg BGM0504 Administered SC — Drug: BGM0504 Administered SC
  • Drug: Drug: : 10 mg BGM0504 Administered SC — Drug: BGM0504 Administered SC
  • Drug: Drug: Placebo Administered SC — Drug: Placebo Administered SC

Primary Outcomes

  • Change From Baseline in Hemoglobin A1c (HbA1c) (Week 0 to Week 32)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-12-02
Completion: 2026-08-25
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 207 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: BrightGene Bio-Medical Technology Co., Ltd.
Collaborators: BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.
Contact Information
Study Contact:
Linong Ji,MD, chief physician, Peking University People's Hospital
+86 13910978815
jiln@bjmu.edu.cn
Linong Ji
+860139010978815
jiln@bjmu.edu.cn
Peking University People's Hospital
Interventions
  • Drug: Drug: 5 mg BGM0504 Administered SC — Drug: BGM0504 Administered SC
  • Drug: Drug: : 10 mg BGM0504 Administered SC — Drug: BGM0504 Administered SC
  • Drug: Drug: Placebo Administered SC — Drug: Placebo Administered SC
Study Locations (1 sites)
Peking University People's Hospital, Beijing, Beijing Municipality 100044 China
Eligibility Criteria
Inclusion Criteria: * ☑ Have been diagnosed with type 2 diabetes mellitus (T2DM); * Have a BMI ≥23 kilograms per meter squared (kg/m²) at screening; * Be of stable weight (± 5%) for at least 3 months before screening; * Have HbA1c between ≥7.5% and ≤11.0%; * Fasting Plasma Glucose (FPG) ≤ 15.0 mmoL/L. Exclusion Criteria: * ■ Previous diagnosis of type 1 diabetes, special type diabetes ; * There are malignant tumors within 5 years before screening, or patients are in latent of clinical malignant tumors (except patients with skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ or papillary thyroid carcinoma who have no recurrence after surgery). * Have had chronic or acute pancreatitis any time prior to study entry; * Known allergic constitution (allergy to 3 or more kinds of food or drugs), or allergy to GLP-1 receptor agonists, or severe allergic diseases (asthma, urticaria, eczematous dermatitis, etc.) at screening; * Mentally incapacitated or speech-impaired; * Suspected or confirmed history of alcohol or drug abuse; * Pregnant or lactating woman; * The investigator considers that there are any other conditions that make it inappropriate to participate in this study.
Conditions Metastatic Breast Cancer
Phase NA
Enrollment 400
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Many people living with metastatic breast cancer face challenging symptoms and frequent medical visits. At the same time, conversations about personal goals, values, and preferences for care may not always happen as early or as often as patients and families would like. This multi-site study will test the effectiveness of a five-session palliative care program, designed specifically for people with metastatic breast cancer and their caregivers, to strengthen communication with clinicians about what matters most in their care. The study aims to inform how palliative care services can be delivered in a more timely, personalized, and scalable way for people living with advanced cancers who have long disease trajectories, such as metastatic breast cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Other: Palliative Care Intervention, "TARGET-PC" — Palliative care intervention focused on eliciting patients' goals and values to facilitate discussion and documentation of health care preferences.
  • Other: Enhanced Usual Care — Oncology clinicians will receive an electronic message to encourage them to discuss and document their patients' health care preferences.

Primary Outcomes

  • Documentation of End-of-Life Care Preferences (From date of randomization until date of death or last follow up assessed up to 60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-01
Completion: 2030-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Cancer Institute (NCI), Duke University, University of Pennsylvania
Contact Information
Study Contact:
Jennifer Temel, MD
617-724-4000
jtemel@mgh.harvard.edu
Joseph Greer, PhD
617-724-4000
jgreer2@mgh.harvard.edu
Jennifer Temel, MD
617-724-4000
jtemel@mgh.harvard.edu
Massachusetts General Hospital
Interventions
  • Other: Palliative Care Intervention, "TARGET-PC" — Palliative care intervention focused on eliciting patients' goals and values to facilitate discussion and documentation of health care preferences.
  • Other: Enhanced Usual Care — Oncology clinicians will receive an electronic message to encourage them to discuss and document their patients' health care preferences.
Study Locations (3 sites)
Massachusetts General Hospital, Boston, Massachusetts 02465 United States
Duke University, Durham, North Carolina 54677 United States
University of Pennsylvania, Philadelphia, Pennsylvania 46205 United States
Eligibility Criteria
Patient Inclusion Criteria: * age ≥18 years * diagnosed with metastatic breast cancer * within 8 weeks of the oncology visit at which they were identified as having an eligible Epic EOL Care Index (≥ 15) * functioning independently per an Eastern Cooperative Oncology Group performance status ≤2 * receiving their cancer care at one of the participating institutions * able to complete questionnaires in English or Spanish Patient Exclusion Criteria: * received outpatient palliative care visit within the last six months * enrolled in hospice services * diagnosed with a comorbid condition that impairs their ability to understand study procedures and/or consent for the trial as per the report of the oncology clinician(s) Caregiver Inclusion Criteria: * age ≥18 years * identified by the patient as a family member or friend who is primarily involved in their care * able to complete questionnaires in English or Spanish
Conditions Major Depressive Disorder (MDD), Depress...
Phase PHASE3
Enrollment 330
Locations 79 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to determine the efficacy, safety and tolerability of CYB003 compared to matching placebo as adjunctive treatment in patients with MDD. For more information about the EMBRACE study, including participating study locations, and to register your interest in learning more about participation, please visit the study website: https://embrace-mdd-trial.com/

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: CYB003 — CYB003 is a deuterated psilocin analog.
  • Behavioral: Psychological Support — Manualized psychological support performed by facilitator.

Primary Outcomes

  • Montgomery-Asberg Depression Scale (MADRS) (Screening Day-45, Baseline, Day -1, Day 21, Day 42, Day 63 and Day 84/End of Trial.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-12-10
Completion: 2027-08-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 330 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cybin IRL Limited
Collaborators: Worldwide Clinical Trials
Principal Investigators:
  • Felix Mazer (STUDY_DIRECTOR) - Cybin IRL Limited
Contact Information
Study Contact:
Clinical Development
877-361-4003
clinicaltrialsinfo@cybin.com
Seher Premani
205-996-1198
spremani@uab.edu
UAB Psychiatry and Behavioral Neurology
Maggie Gossage
mgossage@uabmc.edu
UAB Psychiatry and Behavioral Neurology
Interventions
  • Drug: CYB003 — CYB003 is a deuterated psilocin analog.
  • Behavioral: Psychological Support — Manualized psychological support performed by facilitator.
Study Locations (79 sites)
UAB Psychiatry and Behavioral Neurology, Birmingham, Alabama 35209 United States
Lighthouse Psychiatry, Gilbert, Arizona 85234 United States
Pillar Clinical Research - Little Rock, Little Rock, Arkansas 72204 United States
Behavioral Research Specialists, LLC, Glendale, California 91206 United States
Sun Valley Research Center, Imperial, California 92251 United States
CalNeuro Research Group, Los Angeles, California 90025 United States
Lipov Medical Group, Los Angeles, California 90025 United States
ATP Clinical Research, Orange, California 92866 United States
NRC Research Institute, Orange, California 92868 United States
Inland Psychiatric Medical Group Inc (IPMG Research), San Juan Capistrano, California 92675 United States
Eligibility Criteria
Inclusion Criteria: Participants must meet all the following criteria to be included in the trial: * Age18 to 85 years. * Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR \[if single episode, duration of ≥4 weeks and ≤24 months\] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60. * Moderate to severe depression at Screening and Baseline, independently confirmed. * Participants have been on a stable dose of antidepressant medication (label specified) at an adequate dose in the last 4 weeks prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator. * Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤40 kg/m2), inclusive, at Screening. * Participant is able to refrain from nicotine use during the dosing session (up to 8 hours). * Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential. * Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing. * Participants of non-childbearing potential who are or were capable of producing eggs (ova) must have been postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy. * Participants have provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form. Exclusion Criteria Participants with any of the following characteristics/conditions will be excluded from trial participation: * Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder. * Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD. * Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first-degree relatives). * Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening. * Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview. * Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months. * Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressants, mirtazapine, trazodone, moclobemide, buspirone, or an antipsychotic or mood stabilizer. Note: if receiving these medications are for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1. * Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening. * Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening. * Clinically relevant history of abnormal physical health interfering with the trial (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal \[including dyspepsia or gastroesophageal reflux disease\], hepatic, or renal disorder). * Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication. * Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate. * Participants have a presence or relevant history of organic brain disorders. * Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within prior to trial medication administration. * Donation of blood or plasma within 4 weeks prior to first dosing and until 4 weeks after final dosing. * Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing. * Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing. * History of serotonin syndrome. * Unwilling to consent to audio and video recording of psychological support and dosing sessions.
Conditions Major Depression, Sleep Architecture, Ob...
Phase NA
Enrollment 130
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In a double-blind, parallel-group controlled trial, we aim to measure the effect of two weeks of light therapy combined with the CPAP on compliance CPAP in patients with major depressive disorder.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Light therapy — The intervention consists of 30 minutes of daily exposure to light therapy glasses (active or sham according to randomization) on waking for 2 weeks. The light therapy will be delivered in the patient's home at the same time as CPAP is introduced.

Primary Outcomes

  • CPAP Compliance (1 time :Day 14)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-17
Completion: 2027-10-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hôpital le Vinatier
Principal Investigators:
  • Sébastien S CATOIRE, DR (PRINCIPAL_INVESTIGATOR) - Centre Hospitalier le Vinatier
Contact Information
Study Contact:
Sébastien S CATOIRE, Dr
+330437915495
sebastien.catoire@ch-le-vinatier.fr
Lydie L SARTELET, Mrs
+33(0)437915531
lydie.sartelet@ch-le-vinatier.fr
Interventions
  • Device: Light therapy — The intervention consists of 30 minutes of daily exposure to light therapy glasses (active or sham according to randomization) on waking for 2 weeks. The light therapy will be delivered in the patient's home at the same time as CPAP is introduced.
Study Locations (2 sites)
Centre Hospitalier le Vinatier, Bron, France 69678 France
Centre Hospitalier le Vinatier, Bron, 69678 France
Eligibility Criteria
Inclusion Criteria: * Adults consulting at the MICHEL JOUVET unit, CH Le Vinatier, Bron * Adults with a diagnosis of major depressive episode (DSM-V) and with a MADRS score ≥ 15 * Adults with a diagnosis of OSAS on ventilatory polygraphy or polysomnography (AASM 2017 criteria) requiring CPAP. Exclusion Criteria: * Refusal to participate. * Pregnant and breast-feeding women * Under guardianship or curatorship. * Unstable psychiatric or physical pathology (e.g., hypomania, high suicidal risk) considered incompatible with the study by the investigators. * Other psychiatric, neurologic or somatic conditions * Contraindication to light therapy: retinopathy, retinitis pigmentosa, diabetic retinopathy, macular degeneration, glaucoma, recent eye surgery (less than 3 months). patient wishing to choose a provider other than the protocol provider. * Patient wishing to choose a device other than SEFAM's S-BOX or a mask other than the nasal mask at the time of introduction. * Nasal obstruction. * Refusal to use actimetry, refusal to use light therapy, refusal to use CPAP.
Conditions Diabetes Mellitus, Type 2
Phase PHASE4
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if SGLT2 inhibitor Henggliflozin works to improve glucose variability in type 2 diabetes and if Henggliflozin can benefit immunosenescence. The main questions it aims to answer are: Does Henggliflozin as an add on treatment works to improve blood glucose fluctuation in type 2 diabetes? Does Henggliflozin has extra benefits like improve immunosenescence beyond hypoglycemic effects? Researchers will compare Henggliflozin to a placebo to see if Henggliflozin can improve glucose variability and immunosenescence. Participants will: Take Henggliflozin or a placebo every day for 16 weeks. Receive weekly follow-up calls to guide them in adjusting their insulin doses. Return for an on-site visit at 4 weeks and 16 weeks. Take a continuous glucose monitoring (CGM) for 7 days at the Visit 1 and at the end of the study.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Henggliflozin — Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receiveHenggliflozin 10 mg once daily by oral administration for up to 16 weeks.
  • Other: Placebo — Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receive a placebo once daily by oral administration for up to 16 weeks.

Primary Outcomes

  • Change from Baseline in the mean amplitude of glycemic excursions at 16 weeks (From enrollment to the end of treatment at 16 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-07-14
Completion: 2028-03-30
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Principal Investigators:
  • Qing Su (STUDY_DIRECTOR) - Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Contact Information
Study Contact:
Hongmei Zhang
+8613636347760
spicygirlss@126.com
Hongmei Zhang, PHD
+8613636347760
spicygirlss@126.com
Shanghai Jiaotong University School of Medicine, Xinhua Hospital
Interventions
  • Drug: Henggliflozin — Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receiveHenggliflozin 10 mg once daily by oral administration for up to 16 weeks.
  • Other: Placebo — Upon enrollment, at Visit 1 (baseline), overnight fasting blood and urine samples will be collected, and glucose levels will be monitored for 3-5 days using a continuous glucose monitoring (CGM) system (Medtronic MiniMed). After the preliminary assessment, participants will receive a placebo once daily by oral administration for up to 16 weeks.
Study Locations (1 sites)
Shanghai Jiaotong University School of Medicine, Xinhua Hospital, Shanghai, Shanghai Municipality 200092 China
Eligibility Criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes mellitus (T2DM) for at least 6 months based on the 1999 WHO criteria. * Age between 50 and 70 years at the time of signing the informed consent form (inclusive). * Poor glycemic control despite treatment with basal insulin or insulin degludec/aspart (with or without oral antidiabetic drugs) within the 3 months prior to screening. * HbA1c level above 8%. * BMI ≥ 20 kg/m². * C-peptide levels within the normal reference range. * Able to maintain stable dietary and exercise habits during the study. * Capable of understanding the study procedures and methods, willing to strictly comply with the clinical trial protocol, and voluntarily sign the informed consent form. Exclusion Criteria: * Patients considered by the investigator to have potential allergies to the components of the study drug or drugs of the same class. * Use of SGLT2 inhibitors or GLP-1 receptor agonists within 3 months prior to screening. * Adjustments to antidiabetic treatment regimens within 3 months prior to screening. * Hospitalization due to acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, or unstable angina), percutaneous coronary intervention, or cardiac surgery within 30 days prior to the screening visit. * Volume depletion. * Chronic (\>2 weeks) systemic glucocorticoid therapy or use of glucocorticoids within 4 weeks prior to screening (except for topical, intraocular, intranasal, or inhaled administration). * Pregnancy, lactation, or plans for pregnancy within the next 6 months. * Persistently elevated serum transaminase levels (more than 3 times the upper limit of normal). * Renal impairment (estimated glomerular filtration rate \[eGFR\] \< 45 mL/min/1.73 m²). * History of malignant tumors. * Presence of acute complications (e.g., ketoacidosis, diabetic ketoacidosis, lactic acidosis, or hyperosmolar coma). * Systemic autoimmune diseases, such as systemic lupus erythematosus. * Clinically significant urinary tract infections and/or genital infections, or a history of recurrent urinary tract and/or genital infections. * Any other factors deemed by the investigator to potentially affect the efficacy or safety evaluation of the study. * Participation in other clinical trials and receipt of investigational drugs within 3 months prior to screening.
Conditions Advanced Solid Tumors, HER2 Mutation
Phase PHASE2
Enrollment 111
Locations 54 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how well BAY2927088 (sevabertinib) works in people with different types of solid tumors with HER2 mutations. These include tumors in the colon or rectum, the uterus and the cervix (lower part of the uterus), the breast, the bladder, and the biliary tract (includes gall bladder and bile ducts) as well as other types of solid tumors with the exception of people with advanced non-small cell lung cancer (NSCLC). Solid tumors may have specific changes or mutations to a gene called human epidermal growth receptor-2 (HER2). This leads to the formation of an abnormal form of HER2 protein in the cancer cells, resulting in increased cell growth. The study treatment, BAY2927088, is expected to block the abnormal HER2 protein which may stop the spread of cancer. The trial will include about 111 participants who are at least 18 years old. All the participants will take 20 mg of BAY2927088 as tablets by mouth. The participants will take treatments in 3-week periods called cycles. These 3-week cycles will be repeated throughout the trial. The participants can take BAY2927088 until their cancer gets worse, until they have medical problems, or until they leave the trial. During the trial, the doctors will take imaging scans of different parts of the body to study the spread of cancer and will check heart health using echocardiogram or cardiac magnetic resonance imaging (MRI) and electrocardiogram (ECG). The doctors will also take blood and urine samples and do physical examinations to check the participants' health. They will ask questions about how the participants are feeling and if they have any medical problems.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: BAY2927088 — tablet, oral

Primary Outcomes

  • Objective Response Rate (ORR) per RECIST 1.1 as assessed by BICR (From start of study intervention until the first documented progression, or death from any cause, or end of study (up to approximately 3 years), whichever comes first)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-02-13
Completion: 2029-10-26
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 111 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bayer
Contact Information
Study Contact:
Bayer Clinical Trials Contact
0018888422937
clinical-trials-contact@bayer.com
Interventions
  • Drug: BAY2927088 — tablet, oral
Study Locations (54 sites)
UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham, Alabama 35233 United States
City of Hope - Duarte Cancer Center, Duarte, California 91010 United States
Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers, Florida 33908 United States
Dana-Farber Cancer Institute - Oncology Department, Boston, Massachusetts 02215 United States
Brigette Harris Cancer Pavilion at Henry Ford Cancer Center - Detroit, Detroit, Michigan 48202 United States
Profound Research -OMG - TriAtria Cancer Center, Farmington Hills, Michigan 48334 United States
Cleveland Clinic - Oncology Department, Cleveland, Ohio 44195 United States
SCRI Oncology Partners, Nashville, Tennessee 37203 United States
The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston, Texas 77030 United States
Gynecology Oncology clinic at UW Medical Center - Montlake, Seattle, Washington 98195 United States
Eligibility Criteria
Inclusion Criteria: * Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor cancer (colorectal carcinoma; biliary tract cancer; bladder and urothelial tract cancer; cervical cancer; endometrial cancer; breast cancer; other solid tumor cancer, excluding NSCLC) * Participant must be ≥18 years of age or over the legal age of consent * Patients who have received prior standard therapy appropriate for their tumor type and stage of disease, or who have no satisfactory alternative treatments * Documented activating HER2 mutation * At least one measurable lesion that would qualify as a target lesion by RECIST 1.1 criteria Exclusion Criteria: * Primary diagnosis of non-small cell lung cancer (NSCLC) * Prior treatment with a HER2 tyrosine kinase inhibitor (TKI) * Active brain metastases * Uncontrolled, severe, intercurrent illness
Conditions Uncontrolled Arterial Hypertension
Phase NA
Enrollment 90
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Prospective, single arm trial to assess the effects of renal denervation on day-by-day blood pressure measurements and time in blood pressure target range, as well as establish a multivariate prediction model for blood pressure reduction after renal denervation.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Renal sympathetic denervation — All procedures will be carried out by highly experienced interventional cardiologists, each having performed a minimum of 20 RDN prior to treating study patients. All interventions will be performed with the CE-marked Symplicity SpyralTM (Medtronic, Minneapolis, MN, USA) renal denervation system following current treatment standards. Procedures will be performed as stated in the IFU. The specific ablation points will be determined by the discretion of the interventionalist.

Primary Outcomes

  • Primary endpoint (target range between months 4 to 6 (before renal denervation) vs. 10 to 12 (4 to 6 months after renal denervation))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-01
Completion: 2028-02-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Heart Center Leipzig - University Hospital
Collaborators: Helios Health Institute GmbH
Principal Investigators:
  • Karl Fengler, Dr. med. (PRINCIPAL_INVESTIGATOR) - Heart Center Leipzig
Contact Information
Study Contact:
Philipp Lurz, Prof. Dr. med.
Universitätsmedizin Mainz Kardiologie I
Philipp Lurz, Prof. Dr. med.
Universitätsmedizin Mainz Kardiologie I
Karl Fengler, Dr. med.
+49341865251197
Karl.Fengler@helios-gesundheit.de
Heart Center Leipzig
Interventions
  • Procedure: Renal sympathetic denervation — All procedures will be carried out by highly experienced interventional cardiologists, each having performed a minimum of 20 RDN prior to treating study patients. All interventions will be performed with the CE-marked Symplicity SpyralTM (Medtronic, Minneapolis, MN, USA) renal denervation system following current treatment standards. Procedures will be performed as stated in the IFU. The specific ablation points will be determined by the discretion of the interventionalist.
Study Locations (2 sites)
Universitätsmedizin Mainz Kardiologie I, Mainz, Rheinland Pflanz 55131 Germany
Heart Center Leipzig, Leipzig, Saxony 04289 Germany
Eligibility Criteria
Inclusion Criteria: 1. Confirmed arterial hypertension with systolic or diastolic blood pressure \>140/90 mmHg in standardized office blood pressure measurement 2. Treatment with 3 to ≤5 antihypertensive drug classes 3. Age \>18 years 4. Written informed consent Exclusion Criteria: 1. Age ≤ 18 years 2. anatomy unsuitable for renal denervation (i.e. renal artery stenosis, single functioning kidney) 3. pregnancy 4. patients under legal supervision or guardianship 5. participation in other trials that might interfere with the study outcome according to the opinion of one of the investigators.
Conditions Diabetes Mellitus, Type 2
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: SGLT2 inhibitor — SGLT2 inhibitor class of drugs
  • Drug: Thiazolidinedione — Thiazolidinedione class of drugs
  • Drug: DPP-4 inhibitor — DPP4 inhibitor class of drugs

Primary Outcomes

  • Evaluation of Incidence of Adverse events in Triple Combination Therapy Including Metformin with SGLT-2i, DPP-4i, or TZD Class Drugs. (24 month)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-03-16
Completion: 2029-12-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chong Kun Dang Pharmaceutical
Contact Information
Study Contact:
Soo Lim, M.D, Ph.D.
82-2-6373-0773
limsoo@snu.ac.kr
Soo Lim, M.D, Ph.D.
1588-3369
limsoo@snu.ac.kr
Seoul National University Bundang Hospital
Interventions
  • Drug: SGLT2 inhibitor — SGLT2 inhibitor class of drugs
  • Drug: Thiazolidinedione — Thiazolidinedione class of drugs
  • Drug: DPP-4 inhibitor — DPP4 inhibitor class of drugs
Study Locations (1 sites)
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do South Korea
Eligibility Criteria
Inclusion Criteria: 1. Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment. 2. Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment. 3. 7.0% ≤ HbA1c \< 10.0% based on laboratory tests performed within 4 weeks of enrollment. 4. Voluntarily give written informed consent after being told about the study. Exclusion Criteria: 1. Patients with type 1 diabetes and secondary diabetes. 2. Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment. 3. Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study. 4. End-stage renal disease and hemodialysis patients. 5. diabetic ketoacidosis Patients. 6. Pregnant and lactating women. 7. Patients who are contraindicated by any of the "Precautions for Use" in the license for the drug being administered during the study, given the observational nature of the study under routine practice. 8. Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients. 9. Anyone else deemed by the investigator to be unsuitable for participation in the study.
Conditions Depression - Major Depressive Disorder, ...
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This longitudinal, observational study aims to assess whether the characteristics of a novel blood peripheral biomarker can serve as indicators for depression and schizophrenia in patients at the Royal Columbian Hospital Psychiatric Clinics. The study will evaluate whether changes in these biomarker characteristics can help distinguish between depressed patients who do or do not respond to treatment and between individuals experiencing a single psychotic episode and those at risk of progressing to schizophrenia. To achieve this, blood samples and standardized mental health assessments will be collected across three study visits from up to 500 participants, grouped into two study arms based on their diagnosis: Depression (DEP) or Psychosis/Schizophrenia (PSY).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Relationship between Depression and Biomarker Characteristics (6 months from enrollment, across three study visits.)
  • Relationship between Psychotic Disorders and Biomarker Characteristics (6 months from enrollment, across 3 study visits.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-25
Completion: 2027-08-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fraser Health
Collaborators: Royal Columbian Hospital Foundation
Principal Investigators:
  • Steven Reynolds, MD, FRCPC (PRINCIPAL_INVESTIGATOR) - Royal Columbian Hospital Foundation
Contact Information
Study Contact:
Jessica Wittmann
+1 (236) 332-6575
LeadingMH@fraserhealth.ca
Marlena Ornowska
+1 (236) 332-6575
LeadingMH@fraserhealth.ca
Jessica Wittmann
LeadingMH@fraserhealth.ca
Royal Columbian Hospital
Interventions
N/A
Study Locations (1 sites)
Royal Columbian Hospital, New Westminster, British Columbia V3L 3M2 Canada
Eligibility Criteria
Inclusion Criteria: I. Age 19+. II. Informed consent by participant III. Any of the following situations: 1. Suspected, new onset or established depression. 2. First episode of psychosis or suspected/established schizophrenia. IV. In the opinion of the Investigator, the participant will likely be able to complete the standardized mental health questionnaires administered in each study visit. Exclusion Criteria: I. Inability to provide informed consent. II. Currently enrolled in any other research study involving drugs or devices that may confound mental health treatment outcomes. III. Currently declared on extended leave Under British Columbia's Mental Health Act.
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this prospective study is to evaluate diabetes outcomes after initiating second generation intermittently scanned continuous glucose monitoring (isCGM) plus one pharmacist consultation session compared with capillary blood glucose (CBG) monitoring among insulin-naïve adults with type 2 diabetes (T2D) in a specialist endocrinology clinical setting in Canada. Primary Outcome - To evaluate change in HbA1c at 3-6 months follow-up after initiating isCGM plus one pharmacist consultation (isCGM cohort) compared with CBG monitoring (CBG cohort) among insulin-naïve adults with T2D. Secondary Outcomes - To determine the change in metabolic outcomes and patient reported outcomes (PROs) and number of non-insulin antihyperglycemic agents (AHAs) prescribed from baseline to 3-6 months (± 6 weeks) in the isCGM cohort compared to the CBG cohort. Another secondary outcome is to assess isCGM metrics and number of isCGM discontinuations in the isCGM cohort at 3-6 months (± 6 weeks) compared to baseline. Additionally the study will describe and/or evaluate glycemic and metabolic outcomes, and PROs in participants who initiate an isCGM device and opt to enroll in a diabetes coaching program (isCGM+coaching cohort) at baseline compared to follow-up at 3-6 months (± 6 weeks). Exploratory Outcomes - To compare change in HbA1c between the matched isCGM cohort and CBG cohort by subgroups: age (\< 65 years old vs ≥ 65 years old) and baseline HbA1c (\< 8.5% vs ≥ 8.5%).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Intermittently Scanned Continuous Glucose Monitor — intervention used by the isCGM and isCGM+Coaching groups

Primary Outcomes

  • Change in HbA1c (from enrollment to 3-6 month follow up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-09
Completion: 2026-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: LMC Diabetes & Endocrinology Ltd.
Collaborators: Sun Life Assurance Company of Canada
Contact Information
Study Contact:
Manager, Data Science
4166452929
lisa.chu@lmc.ca
LMC Diabetes & Endocrinology Ltd.
Research Assistant, Data Science
giovana.romero@lmc.ca
LMC Diabetes & Endocrinology Ltd.
Interventions
  • Device: Intermittently Scanned Continuous Glucose Monitor — intervention used by the isCGM and isCGM+Coaching groups
Study Locations (1 sites)
LMC Diabetes & Endocrinology Ltd., Toronto, Ontario M4G 3E8 Canada
Eligibility Criteria
Inclusion Criteria: * 18 years or older * Clinical diagnosis of T2D ≥ one year * Using at least one AHA * Status as a Sun Life group benefits member, initiates isCGM device through Lumino Health™ Pharmacy, and completes one initial pharmacist consultation (isCGM cohort) or completes 2 or more diabetes coaching program consultations (isCGM+coaching cohort); or has private health insurance and uses CBG monitoring (CBG cohort) * Baseline HbA1c ≥ 7.0% * ≥ 1 HbA1c value up to 6 months prior to index date * Exclusive use of isCGM for ≥ 3 months * Informed consent Exclusion Criteria: * Have a history of insulin use * Are pregnant or breastfeeding at the time of study enrollment or become pregnant during the study * Have an estimated glomerular filtration rate (eGFR) \< 30 ml/min/1.73m2 * Previously used rtCGM or isCGM for \> 3 months * Recent or expectant change to antihyperglycemic medications or doses within 30 days of index date